Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma.

Laura M Madanat-HarjuojaKelly KlegaYao LuDavid S ShulmanAaron R ThornerAnwesha NagWilliam D TapDenise K ReinkeLisa DillerKarla V BallmanSuzanne GeorgeBrian D Crompton

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Our results demonstrate that detection of ctDNA is associated with outcome and objective response to chemotherapy in patients with advanced LMS. These results suggest that liquid biopsy assays could be used to inform treatment decisions by recognizing patients who are likely and unlikely to benefit from chemotherapy. See related commentary by Kasper and Wilky, p. 2480.

Keyphrases

circulating tumor
cell free
circulating tumor cells
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
locally advanced
prognostic factors
peritoneal dialysis
high throughput
ionic liquid
ultrasound guided
single molecule
combination therapy
label free
replacement therapy
nucleic acid